Literature DB >> 1462164

The National Cancer Institute: cancer drug discovery and development program.

M R Grever1, S A Schepartz, B A Chabner.   

Abstract

The discovery and development of novel therapeutic products for the treatment of malignancy is vitally important to those physicians responsible for the management of cancer patients. A description of the ongoing efforts at the National Cancer Institute (NCI) is intended to provide insight into those complex processes necessary to accomplish this mission. An update on the NCI's revised cancer screen is accompanied by a brief summary of those new agents scheduled to be entered into clinical investigation in the near future. The tremendous potential advantages and challenges associated with the use of a molecular approach to cancer drug design are discussed. Despite the differences of opinion that may exist regarding the optimal strategies for accomplishing the mission, there is no disagreement regarding the importance of the effort to find effective new therapies for cancer patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1462164

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  87 in total

Review 1.  The complexity of radiation stress responses: analysis by informatics and functional genomics approaches.

Authors:  A J Fornace; S A Amundson; M Bittner; T G Myers; P Meltzer; J N Weinsten; J Trent
Journal:  Gene Expr       Date:  1999

2.  Chemosensitivity prediction by transcriptional profiling.

Authors:  J E Staunton; D K Slonim; H A Coller; P Tamayo; M J Angelo; J Park; U Scherf; J K Lee; W O Reinhold; J N Weinstein; J P Mesirov; E S Lander; T R Golub
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

3.  Two new eicosanoids with a unique isovalerianic acid ester moiety from the South China Sea gorgonian Dichotella gemmacea.

Authors:  Chang-Yun Wang; Jie Zhao; Hai-Yan Liu; Chang-Lun Shao; Qing-Ai Liu; Yang Liu; Yu-Cheng Gu
Journal:  Lipids       Date:  2010-11-16       Impact factor: 1.880

4.  Aegicerin, the first oleanane triterpene with wide-ranging antimycobacterial activity, isolated from Clavija procera.

Authors:  Rosario Rojas; Luz Caviedes; José C Aponte; Abraham J Vaisberg; Walter H Lewis; Gerardo Lamas; César Sarasara; Robert H Gilman; Gerald B Hammond
Journal:  J Nat Prod       Date:  2006-05       Impact factor: 4.050

5.  Inhibition on Hepatitis B virus in vitro of recombinant MAP30 from bitter melon.

Authors:  Jian Ming Fan; Qiao Zhang; Jun Xu; Sha Zhu; Tao Ke; De Fu Gao; Yu Bao Xu
Journal:  Mol Biol Rep       Date:  2007-12-05       Impact factor: 2.316

6.  Effects of recombinant MAP30 on cell proliferation and apoptosis of human colorectal carcinoma LoVo cells.

Authors:  Jian-Ming Fan; Jun Luo; Jun Xu; Sha Zhu; Qiao Zhang; De-Fu Gao; Yu-Bao Xu; Gai-Ping Zhang
Journal:  Mol Biotechnol       Date:  2008-02-01       Impact factor: 2.695

7.  Synthesis and evaluation of functionalized indoles as antimycobacterial and anticancer agents.

Authors:  Gökçe Cihan-Üstündağ; Gültaze Capan
Journal:  Mol Divers       Date:  2012-08-15       Impact factor: 2.943

8.  Discovery of a clinical stage multi-kinase inhibitor sodium (E)-2-{2-methoxy-5-[(2',4',6'-trimethoxystyrylsulfonyl)methyl]phenylamino}acetate (ON 01910.Na): synthesis, structure-activity relationship, and biological activity.

Authors:  M V Ramana Reddy; Padmavathi Venkatapuram; Muralidhar R Mallireddigari; Venkat R Pallela; Stephen C Cosenza; Kimberly A Robell; Balaiah Akula; Benjamin S Hoffman; E Premkumar Reddy
Journal:  J Med Chem       Date:  2011-08-17       Impact factor: 7.446

9.  Improved production of bioactive glucosylmannosyl-glycerolipid by sponge-associated Microbacterium species.

Authors:  Siegmund Lang; Winfried Beil; Harukumi Tokuda; Corinna Wicke; Verena Lurtz
Journal:  Mar Biotechnol (NY)       Date:  2004-04-19       Impact factor: 3.619

10.  Comparison of doxorubicin concentration profiles in radiofrequency-ablated rat livers from sustained- and dual-release PLGA millirods.

Authors:  Feng Qian; Nicholas Stowe; Gerald M Saidel; Jinming Gao
Journal:  Pharm Res       Date:  2004-03       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.